drugset

drugset / Trial / NCT00652457

Study of Memantine to Treat Huntington's Disease

NCT00652457 ↗

Phase 4 Completed 50 enrolled Jody Corey-Bloom, MD, PhD Forest Laboratories · collab

RandomizedCrossoverQuadruple-blindTreatment

Summary

To determine if memantine in doses of 10 mg BID affects memory, cognition, and behavior in patients with Huntington's disease (HD).

Timeline

Start: 2004-11-23
Primary completion: 2009-10-28
Completion: 2009-10-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Memantine	Unknown	10 mg	—

Indications